Statistically evaluate the role of CD56 and p63 in the diagnosis of PTC and differentiating them from PTC mimickers
##plugins.themes.academic_pro.article.main##
Abstract
Abstract
Introduction
The coastal belt of Kerala is known for its radiation hazard and the increased incidence of thyroid disorders including PTC. PTC, if it shows classical histology is easy to diagnose. However, a lot of being or non neoplastic lesions mimic PTC and then the diagnostic dilemma arises, hence, the need for a specific marker to diagnose PTC.
Aim and objective
With this background in mind this study was conducted to evaluate the usefulness of CD56 and p63 IHC markers as diagnostic tools for PTC.
Materials and method
This was a descriptive study conducted over a period of 18 months in the Dept ofPathology at GTDMC, Alappuzha. 100 consequetive thyroidectomy specimens received in the Dept were included in the study. The exclusion criterion was all pure colloid goiters which never pose as mimics of PTC. The specimens were studied for morphology and IHC done as per protocol with CD56 and p63 markers. A positive membranous staining without a cytoplasmic staining in 10% or more neoplastic cell is considered as positive staining for CD56 and any nuclear staining is counted as positive for p63. The findings were analyzed and sensitivity, specificity, PPV and NPV were calculated for these markers.
Results
There were 34 cases of PTC and 33 showed negative staining with CD56, giving a Sensitivity of 97.1%, Specificity of 88.9%, Positive predictive value of 82.5% and a Negative predictive value of 98.2%. With p63, Sensitivity was 37.1%, Specificity 92.2%, positive predictive value 72.2%
And Negative predictive value was 72.8%.other malignancies obtained include, Hurthle cell Carcinoma and Follicular Carcinoma.
Conclusion
Hence to conclude, a combined panel of CD56 and p63 is very accurate in diagnosing PTC and differentiating it from its mimickers.
Key words
PTC mimickers, CD56, p63, thyroid neoplasms
##plugins.themes.academic_pro.article.details##
References
-
References
1. Rosai, J. (2011). Rosai and Ackerman's surgical pathology e-book. Elsevier Health Sciences.
2. Menon, U., Sundaram, K. R., Unnikrishnan, A. G., Jayakumar, R. V., Nair, V., & Kumar, H. (2009). High prevalence of undetected thyroid disorders in an iodine sufficient adult south Indian population. Journal of the Indian Medical Association, 107(2), 72-77.
3. James, R., & Kumar, V. (2012). Study on the prevalence of thyroid diseases in Ernakulam city and Cherthala town of Kerala state, India. International Journal of Scientific and Research Publications, 2(2), 1-3.
4. Mokhtari, M., Eftekhari, M., & Tahririan, R. (2013). Absent CD56 expression in papillary thyroid carcinoma: A finding of potential diagnostic value in problematic cases of thyroid pathology. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences, 18(12), 1046.
5. Jeong, J. Y., Jung, J. H., & Park, J. Y. (2016). Expression and diagnostic availability of p63 and CD56 in papillary thyroid carcinoma. Int J Clin Exp Pathol, 9(7), 7402-7410.
6. Ceyran, A. B., Şenol, S., Şimşek, B. Ç., Sağıroğlu, J., & Aydın, A. (2015). Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin. International Journal of Clinical and Experimental Pathology, 8(4), 3670.
7. El Demellawy, D., Nasr, A., & Alowami, S. (2008). Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagnostic pathology, 3(1), 1-12.
8. Shin, M. K., Kim, J. W., & Ju, Y. S. (2011). CD56 and high molecular weight cytokeratin as diagnostic markers of papillary thyroid carcinoma. Korean J Pathol, 45(5), 477.
9. Etem, H., ÖZEKİnCİ, S., Mizrak, B., & ŞEnTüRK, S. (2010). The role of CD56, HBME-1, and p63 in follicular neoplasms of the thyroid. Turk J Pathol, 26(3), 238-42.
10. Preto, A., Reis-Filho, J. S., Ricardo, S., & Soares, P. (2002). P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. Pathology-Research and Practice, 198(7), 449-454.
11. Kim, Y. W., Do, I. G., & Park, Y. K. (2006). Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas. Pathology-Research and practice, 202(11), 759-765.
12. Burstein, D. E., Nagi, C., Wang, B. Y., & Unger, P. (2004). Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and Hashimoto’s thyroiditis: a stem cell hypothesis of papillary carcinoma oncogenesis. Human pathology, 35(4), 465-473.